# A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed 

Source: https://onco.cc/trials/nct05372354/  
OnCo record `nct05372354` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Mezigdomide, Tazemetostat, Trametinib in multiple myeloma, run by Bristol-Myers Squibb, now recruiting.

## Summary

A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma is a phase 1/2 interventional study registered as NCT05372354 by Bristol-Myers Squibb, with 260 participants planned, started 2022-10-18 and due to reach its primary completion in 2026-10-12. Interventions recorded: CC-92480, Tazemetostat, BMS-986158, Trametinib, Dexamethasone. Conditions listed: Multiple Myeloma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT05372354
- Phase: 1/2
- Setting: An Exploratory Phase 1b/2a Multicenter, Open-Label, Novel-Novel Combination Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of CC-92480 (BMS-986348) in Novel Therapeutic Combinations in Participants With Relapsed or Refractory Multiple Myeloma
- Sponsor: Bristol-Myers Squibb
- Enrolled: 260

## Sources

- ClinicalTrials.gov NCT05372354: https://clinicaltrials.gov/study/NCT05372354

## Connected records

- cancers: [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/)
- drugs: [Dexamethasone](https://onco.cc/drugs/dexamethasone/), [Mezigdomide](https://onco.cc/drugs/mezigdomide/), [Tazemetostat](https://onco.cc/drugs/tazemetostat/), [Trametinib](https://onco.cc/drugs/trametinib/)
- companies: [Bristol Myers Squibb](https://onco.cc/companies/bms/)

---
JSON: https://onco.cc/api/v1/entities/nct05372354.json